-
公开(公告)号：KR100957555B1
公开(公告)日：2010-05-11
申请号：KR1020070140139
申请日：2007-12-28
Applicant: 덕성여자대학교 산학협력단
Abstract: 본 발명은 Ras 융합 단백질에 관한 것으로서, 보다 상세하게는 N-Ras 단백질의 일부 영역과 H-Ras 단백질의 일부 영역이 결합되어 다양한 종류의 Ras 단백질 신호전달 경로와 암 발생과의 연관 관계를 확인하는데 유용하게 사용될 수 있는 Ras 융합 단백질, 이를 코딩하는 유전자 및 상기 Ras 융합 단백질을 발현하는 형질전환체에 관한 것이다. 본 발명의 Ras 융합 단백질은 암의 발생 및/또는 전이를 억제할 수 있는 분자 표적 암치료법의 개발 및 바이오 신약의 발굴에 유용하게 사용될 수 있다.
Ras, 융합 단백질, 암 전이-
公开(公告)号：KR1020130009084A
公开(公告)日：2013-01-23
申请号：KR1020110069920
申请日：2011-07-14
Applicant: 덕성여자대학교 산학협력단
IPC: A61K36/8984 , A61K31/015 , A61P35/00
CPC classification number: A61K31/122 , A61K36/8984
Abstract: PURPOSE: A pharmaceutical composition containing a Dendrobium moniliforme extract and denbinobin for anti-gastric cancer is provided to suppress expression of S100A8 protein and reduce infiltration. CONSTITUTION: A pharmaceutical composition for anti-gastric cancer contains a Dendrobium moniliforme extract and a pharmaceutically acceptable salt as an active ingredient. The pharmaceutical composition for anti-gastric cancer contains denbinobin and a pharmaceutically acceptable carrier as an active ingredient. The therapeutically effective amount of denbinobin is 0.01-25%. Denbinobin is extracted from Dendrobium moniliforme or chemically synthesized. The pharmaceutical composition is used by oral administration or parenteral administration.
Abstract translation: 目的：提供含有石斛龙骨提取物和丹参素用于抗胃癌的药物组合物，以抑制S100A8蛋白的表达并减少浸润。 构成：用于抗胃癌的药物组合物含有石斛提取物和药学上可接受的盐作为活性成分。 用于抗胃癌的药物组合物含有丹参蛋白和药学上可接受的载体作为活性成分。 丹参素的治疗有效量为0.01〜25％。 丹参素从石斛石斛提取或化学合成。 药物组合物通过口服给药或肠胃外给药使用。
-
公开(公告)号：KR1020090072132A
公开(公告)日：2009-07-02
申请号：KR1020070140139
申请日：2007-12-28
Applicant: 덕성여자대학교 산학협력단
Abstract: A Ras fusion protein, which a part of N-Ras protein and a part of H-Ras protein are combined, is provided to identify interaction between Ras protein signal pathway and cancer generation and develop the molecule target cancer theraphy. A Ras fusion protein has a form which the first to nth amino acid of a N-Ras (neuroblastoma-Ras) protein and n+1th to 189th amino acid of H-Ras(Harvey-Ras) protein are combined, and n is integer under 165. The fusion protein has the combination form of 1-120th amino acid of N-Ras protein and 121-189th amino acid of H-Ras protein. The fusion protein has the combination form of 1-141th amino acid of N-Ras protein and 142-189th amino acid of H-Ras protein. The fusion protein has the combination form of 1-165th amino acid of N-Ras protein and 166-189th amino acid of the H-Ras protein. The 12th amino acid of the fusion protein is substituted with Asp for Gly.
Abstract translation: 提供Ras融合蛋白，其一部分N-Ras蛋白和部分H-Ras蛋白被组合，以鉴定Ras蛋白信号通路与癌症生成之间的相互作用并开发分子靶标癌症。 Ras融合蛋白具有N-Ras（神经母细胞瘤-Ras）蛋白的第一至第n个氨基酸和H-Ras（Harvey-Ras）蛋白的n + 1至189个氨基酸的组合形式，并且n是整数 融合蛋白具有N-Ras蛋白的第1-120个氨基酸和H-Ras蛋白的第121-189个氨基酸的组合形式。 融合蛋白具有N-Ras蛋白的第1-141位氨基酸和H-Ras蛋白的第142-189位氨基酸的组合形式。 融合蛋白具有N-Ras蛋白1-165位氨基酸和H-Ras蛋白166-189位氨基酸的组合形式。 融合蛋白的第12个氨基酸被Asp取代为Gly。
-
-
Search Results
3
records
(took 0.02 seconds)
